nach oben

Erschienen in:

01.09.2009 | Original Article

Cancer screening using ¹⁸F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report

verfasst von: Jeong Won Lee, Keon Wook Kang, Jin Chul Paeng, Sang Mi Lee, Su Jin Jang, June-Key Chung, Myung Chul Lee, Dong Soo Lee

Erschienen in: Annals of Nuclear Medicine | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study was performed to evaluate the clinical value of ¹⁸F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) for cancer screening in Korean asymptomatic people.

Methods

Between February 2004 and December 2006, 1,587 asymptomatic individuals underwent FDG PET/CT as part of a cancer screening program with some other diagnostic tests at the healthcare center of our hospital. After excluding patients with a history of malignant tumor, 1,336 subjects were enrolled. All PET/CT images were visually analyzed. In subjects showing positive findings for PET/CT or other screening tests, further diagnostic tests and pathological confirmation were performed.

Results

Of the 1,336 subjects, malignant tumors were found in 16 participants (1.2%, thyroid cancer: 9, lung cancer: 2, stomach cancer: 2, and others: 4). There were 47 cases (3.6%) of positive PET/CT findings—11 cases were true positive (thyroid cancer: 8, lung cancer: 1, renal cancer: 1, and invasive thymoma), and 36 false positive, and five cases were false negative. The overall detection rate of PET/CT was 0.8%, and the sensitivity, specificity, positive-predictive value, and negative-predictive value of PET/CT were 68.8, 97.2, 23.4, and 99.6%, respectively.

Conclusions

Fluorodeoxyglucose positron-emission tomography has the potential to detect various kinds of malignant tumors in cancer screening test, and the overall detection rate of PET/CT was 0.8%. FDG PET/CT can be a useful cancer screening modality with the selection of high-risk group and appropriate combination with other screening modalities.

Barratt A, Mannes P, Irwig L, Trevena L, Craig J, Rychetnik L. Cancer screening. J Epidemiol Community Health. 2002;56:899–902.PubMedCrossRef

Rohren EM, Turkington TG, Coleman RE. Clinical application of PET in oncology. Radiology. 2004;231:305–32.PubMedCrossRef

Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening. Ann Nucl Med. 2007;21:65–72.PubMedCrossRef

Chen YK, Ding HJ, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res. 2004;24:4103–8.PubMed

Ghotbi N, Iwanaga M, Ohtsuru A, Ogawa Y, Yamashita S. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Asian Pac J Cancer Prev. 2007;8:93–7.PubMed

Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med. 2000;25:905–10.PubMedCrossRef

Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in the evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–9.PubMed

Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS. The value of F-18 fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma. 2003;50:217–21.PubMed

Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body F-18 FDG-PET scans: the Nishidai clinic study. Eur J Cancer. 2007;43:1842–8.PubMedCrossRef

10.

Ko DH, Choi JY, Song Y, Lee SJ, Kim YH, Lee K, et al. The usefulness of 18F-FDG PET as a cancer screening test. Nucl Med Mol Imaging. 2008;42:444–50.

11.

Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma S, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007;21:481–98.PubMedCrossRef

12.

Terauchi T, Murano T, Daisaki H, Kanou D, Shoda H, Kakinuma R, et al. Evaluation of whole-body cancer screening using 18F–2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008;22:379–85.PubMedCrossRef

13.

Cook GJ. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging. 2007;51:235–43.PubMed

14.

Yasuada S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer. 2000;83:1607–11.CrossRef

15.

Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathologic findings. Eur J Nucl Med Mol Imaging. 2003;30:288–95.PubMed

16.

Higashi K, Ueda Y, Seki H, Oguchi M, Nambu Y, Ueda Y, et al. Flurine-18-FDG imaging is negative in bronchioalveolar lung carcinoma. J Nucl Med. 1998;39:1016–20.PubMed

17.

WHO Fact sheets. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html.

18.

Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.PubMed

19.

Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565–74.PubMedCrossRef

20.

Recommendations of the International Commission on Radiological Protection. ICRP publication no. 60. Oxford: Pergamon; 1991.

21.

Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screening? Against. Eur J Nucl Med Mol Imaging. 2005;32:342–3.PubMedCrossRef

Titel: Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report
verfasst von: Jeong Won Lee
Keon Wook Kang
Jin Chul Paeng
Sang Mi Lee
Su Jin Jang
June-Key Chung
Myung Chul Lee
Dong Soo Lee
Publikationsdatum: 01.09.2009
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 7/2009
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-009-0291-z

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Predictor of underlying myocardial damage in normally functioning left ventricle with narrow QRS complex: relationship between QRS duration at right ventricle pacing and iodine-123 metaiodobenzylguanidine myocardial scintigraphy

11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness

Evaluation of dynamic row-action maximum likelihood algorithm reconstruction for quantitative 15O brain PET

A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity

Direct radionuclide cystography imaging in colovesical fistula due to inguinal hernia operation complication

Predictive value of cardiac autonomic indexes and MIBG washout in ICD recipients with mild to moderate heart failure